Trial Profile
A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Particle Sizes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Dec 2018
Price :
$35
*
At a glance
- Drugs Evacetrapib (Primary)
- Indications Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 15 Dec 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 20 Nov 2015 Planned End Date changed from 1 Dec 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov.
- 20 Nov 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov.